Recent developments in targeting eosinophil accumulation as a novel therapeutic approach for asthma

Garry M Walsh, Alexander J Robinson , Ping Wu Wu

Research output: Contribution to journalLiterature review

Abstract

Current therapies for asthma are aimed at controlling disease symptoms and for the majority of patients inhaled
glucocorticoid anti-inflammatory therapy is both effective and well-tolerated. However, concerns remain about the adverse
effects of glucocorticoids while a subset of asthmatic patients remains symptomatic despite optimal treatment
thereby creating a clear unmet medical need. There is considerable evidence that implicates eosinophils as important effector
cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies
have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including
the selectins, ICAM-1, VCAM-1 together with many of the 1 and 2 integrins. A large body of evidence has
also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation.
Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the
processes controlling eosinophil accumulation in asthma. This review will summarise the problems and successes regarding
recent developments in therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic
lung.
Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalThe Open Allergy Journal
Volume1
DOIs
Publication statusPublished - 2008

Fingerprint

Eosinophils
Asthma
Inflammation
Transendothelial and Transepithelial Migration
Therapeutics
Selectins
Vascular Cell Adhesion Molecule-1
Immunologic Factors
Cell Adhesion Molecules
Intercellular Adhesion Molecule-1
Chemokines
Integrins
Glucocorticoids
Anti-Inflammatory Agents
Cytokines

Cite this

Recent developments in targeting eosinophil accumulation as a novel therapeutic approach for asthma. / Walsh, Garry M; Robinson , Alexander J; Wu, Ping Wu.

In: The Open Allergy Journal , Vol. 1, 2008, p. 35-41.

Research output: Contribution to journalLiterature review

@article{e75161224028495ebd7d6eec0cdd9523,
title = "Recent developments in targeting eosinophil accumulation as a novel therapeutic approach for asthma",
abstract = "Current therapies for asthma are aimed at controlling disease symptoms and for the majority of patients inhaled glucocorticoid anti-inflammatory therapy is both effective and well-tolerated. However, concerns remain about the adverse effects of glucocorticoids while a subset of asthmatic patients remains symptomatic despite optimal treatment thereby creating a clear unmet medical need. There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and 2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise the problems and successes regarding recent developments in therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.",
author = "Walsh, {Garry M} and Robinson, {Alexander J} and Wu, {Ping Wu}",
year = "2008",
doi = "10.2174/1874838400801010035",
language = "English",
volume = "1",
pages = "35--41",
journal = "The Open Allergy Journal",
issn = "1874-8384",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Recent developments in targeting eosinophil accumulation as a novel therapeutic approach for asthma

AU - Walsh, Garry M

AU - Robinson , Alexander J

AU - Wu, Ping Wu

PY - 2008

Y1 - 2008

N2 - Current therapies for asthma are aimed at controlling disease symptoms and for the majority of patients inhaled glucocorticoid anti-inflammatory therapy is both effective and well-tolerated. However, concerns remain about the adverse effects of glucocorticoids while a subset of asthmatic patients remains symptomatic despite optimal treatment thereby creating a clear unmet medical need. There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and 2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise the problems and successes regarding recent developments in therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.

AB - Current therapies for asthma are aimed at controlling disease symptoms and for the majority of patients inhaled glucocorticoid anti-inflammatory therapy is both effective and well-tolerated. However, concerns remain about the adverse effects of glucocorticoids while a subset of asthmatic patients remains symptomatic despite optimal treatment thereby creating a clear unmet medical need. There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and 2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise the problems and successes regarding recent developments in therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.

U2 - 10.2174/1874838400801010035

DO - 10.2174/1874838400801010035

M3 - Literature review

VL - 1

SP - 35

EP - 41

JO - The Open Allergy Journal

JF - The Open Allergy Journal

SN - 1874-8384

ER -